Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Directed evolution of gene-shuffled IFN-alpha molecules with activity profiles tailored for treatment of chronic viral diseases.

Brideau-Andersen AD, Huang X, Sun SC, Chen TT, Stark D, Sas IJ, Zadik L, Dawes GN, Guptill DR, McCord R, Govindarajan S, Roy A, Yang S, Gao J, Chen YH, Skartved NJ, Pedersen AK, Lin D, Locher CP, Rebbapragada I, Jensen AD, Bass SH, Nissen TL, Viswanathan S, Foster GR, Symons JA, Patten PA.

Proc Natl Acad Sci U S A. 2007 May 15;104(20):8269-74. Epub 2007 May 9.

2.

Discovery and directed evolution of a glyphosate tolerance gene.

Castle LA, Siehl DL, Gorton R, Patten PA, Chen YH, Bertain S, Cho HJ, Duck N, Wong J, Liu D, Lassner MW.

Science. 2004 May 21;304(5674):1151-4.

3.
4.

New and modified interferon alfas: preclinical and clinical data.

Masci P, Bukowski RM, Patten PA, Osborn BL, Borden EC.

Curr Oncol Rep. 2003 Mar;5(2):108-13. Review.

PMID:
12583827
5.

Evolution of a human immunodeficiency virus type 1 variant with enhanced replication in pig-tailed macaque cells by DNA shuffling.

Pekrun K, Shibata R, Igarashi T, Reed M, Sheppard L, Patten PA, Stemmer WP, Martin MA, Soong NW.

J Virol. 2002 Mar;76(6):2924-35.

6.

Advances in directed protein evolution by recursive genetic recombination: applications to therapeutic proteins.

Kurtzman AL, Govindarajan S, Vahle K, Jones JT, Heinrichs V, Patten PA.

Curr Opin Biotechnol. 2001 Aug;12(4):361-70. Review.

PMID:
11551464
7.

Evolution of a cytokine using DNA family shuffling.

Chang CC, Chen TT, Cox BW, Dawes GN, Stemmer WP, Punnonen J, Patten PA.

Nat Biotechnol. 1999 Aug;17(8):793-7.

PMID:
10429246
8.

Applications of DNA shuffling to pharmaceuticals and vaccines.

Patten PA, Howard RJ, Stemmer WP.

Curr Opin Biotechnol. 1997 Dec;8(6):724-33. Review.

PMID:
9425664
9.

Structural insights into the evolution of an antibody combining site.

Wedemayer GJ, Patten PA, Wang LH, Schultz PG, Stevens RC.

Science. 1997 Jun 13;276(5319):1665-9. Erratum in: Science 1997 Sep 5;277(5331):1423.

10.

Crystal structures of the free and liganded form of an esterolytic catalytic antibody.

Wedemayer GJ, Wang LH, Patten PA, Schultz PG, Stevens RC.

J Mol Biol. 1997 May 2;268(2):390-400.

PMID:
9159478
11.

The immunological evolution of catalysis.

Patten PA, Gray NS, Yang PL, Marks CB, Wedemayer GJ, Boniface JJ, Stevens RC, Schultz PG.

Science. 1996 Feb 23;271(5252):1086-91.

PMID:
8599084
12.

Directed evolution studies with combinatorial libraries of T4 lysozyme mutants.

Patten PA, Sonoda T, Davis MM.

Mol Divers. 1996 Feb;1(2):97-108.

PMID:
9237198
13.

Expression studies of catalytic antibodies.

Ulrich HD, Patten PA, Yang PL, Romesberg FE, Schultz PG.

Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11907-11.

14.

Transfer of putative complementarity-determining region loops of T cell receptor V domains confers toxin reactivity but not peptide/MHC specificity.

Patten PA, Rock EP, Sonoda T, Fazekas de St Groth B, Jorgensen JL, Davis MM.

J Immunol. 1993 Mar 15;150(6):2281-94.

PMID:
7680688
15.

A genetic approach to the generation of antibodies with enhanced catalytic activities.

Lesley SA, Patten PA, Schultz PG.

Proc Natl Acad Sci U S A. 1993 Feb 15;90(4):1160-5.

16.

A possible basis for major histocompatibility complex-restricted T-cell recognition.

Davis MM, Chien YH, Bjorkman PJ, Elliott JF, Iwashima M, Rock EP, Patten PA.

Philos Trans R Soc Lond B Biol Sci. 1989 Jun 12;323(1217):521-4.

PMID:
2569209
17.

The adult T-cell receptor delta-chain is diverse and distinct from that of fetal thymocytes.

Elliott JF, Rock EP, Patten PA, Davis MM, Chien YH.

Nature. 1988 Feb 18;331(6157):627-31.

PMID:
2963227

Supplemental Content

Loading ...
Support Center